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+ MODEL1. Introduction
Degenerative aortic valve stenosis (AS) is burdensome for
Western societies given the continuously increasing pop-
ulation that reaches 70, 80 or even 90 years of age. For
many decades, surgical aortic valve replacement (SAVR)
has been, and still is, the gold standard for effectively
treating patients with AS to ameliorate symptoms and
extend life. Nonetheless, approximately 30% of patients
are not offered SAVR due to increased surgical risk or
anatomical variations.1e4 Transcatheter aortic valve im-
plantation (TAVI) has emerged in the last decade as an
alternative to SAVR and has become the mainstay of
treatment for inoperable or high-surgical-risk patients
with severe AS.5,6 As the technology and operator expe-
rience advances, even patients with a moderate surgical
risk tend to undergo TAVI. Proper multidisciplinary pre-
and peri-procedural patient evaluation and management
is mandatory for achieving the best outcomes, especially
in patients who could otherwise be effectively treated
surgically. Cardiac anesthesiologists play an important
role in the decision making5 and peri-TAVI care of these
patients in the catheterization laboratory. The aim of this
review is to briefly discuss the TAVI procedure from an
anesthetist’s point of view, focusing on anesthetic man-
agement during TAVI, and to present the current data
regarding the use of general anesthesia (GA) versus local
anesthesia (LA) with conscious sedation, while high-
lighting the gaps in knowledge.2. Pre-procedural evaluation
A Heart Team comprised of cardiologists, interventional
cardiologists, heart surgeons and imaging specialists as-
sesses the suitability of all patients with aortic valve ste-
nosis for SAVR or TAVI. All patients are evaluated in a
detailed fashion and undergo several examinations,
including (but not limited to) an echocardiogram, coronary
angiogram and computed tomography scan. The decision to
perform TAVI is based on the severity of symptoms, evalu-
ation of risks and consideration of special (relative) con-
traindications to open heart surgery, such as previous heart
surgery, ‘hostile’ chest, and severe respiratory failure.
Surgical risk scores, such as the EuroSCORE (1 and 2)7,8 and
STS score9 are also considered, but they have many prob-
lems.10 Functional capability (for example, determined
with the Karnofsky index) can also provide valuable infor-
mation for decision-making.11 During the multidisciplinary
meeting where the access route and valve type are
considered, the input from the anesthesiologist regarding
the risk of the procedure and the type of anesthesia that
will be used is crucial.
The day before the procedure, the anesthesiologist has a
separate, detailed conversation with the patient, explain-
ing all anesthesia-related manipulations and possible com-
plications. Afterwards, the Anesthesia Informed Consent
form is signed. Pre-medication consists of omeprazole 40
mg and bromazepam, 1.5 mg per os the night before, and
the patient fasts for 8 h regardless of the anesthesia
technique that will be employed.Please cite this article in press as: Melidi E, et al., Cardio-anesthesiolo
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TAVI is performed in the cardiac catheterization laboratory
(i.e., cath lab) or in a hybrid operating room under strict
sterile conditions. Cardiac surgical backup in the hospital,
but not necessarily in the room, is mandatory.5,12 Although
the transfemoral route is considered to be the default and
best option for the procedure,13 other routes are available,
including the subclavian,14 trans-aortic15 and trans-apical
approaches.16 In a minority of patients, the arterial
vasculature is not accessible, and the trans-caval route is
another option in these cases.17,18
The availability of transcatheter valves has radically
increased in the past few years, and there is a vast selection of
available sizes that can be selected according to patient’s
anatomical characteristics as well as the operator and center
preference.19,20 The two most widely used valves are the
Edwards family (Edwards Lifesciences, Irvine, USA) and Med-
tronic family (Medtronic, Minnesota, USA) bioprosthetic valves.
The Edwards SAPIEN XT and SAPIEN 3 prostheses are balloon-
expandable and require aortic valve balloon predilatation and
rapid ventricular pacing (RVP) during deployment. The Med-
tronic CoreValve and Evolut R prostheses are self-expandable,
partially or wholly recapturable and repositionable.21 The
latter characteristic has reduced the incidence of implantation
of a second valve as a bail-out maneuver.22
TheMedtronic valves canalso be safely implantedwithout
balloon predilatation.23,24 Both valves can be implantedwith
the trans-femoral approach, but the Edwards valves can also
be implanted trans-apically, whereas the Medtronic valves
can be implanted by the subclavian and direct aortic routes.
Large randomized trials, including the PARTNER25e27 and
CoreValve US28e30 trials, have provided useful insight
regarding the mortality and complication rates after TAVI
with the two most widely used valves.
In recent years, even more TAVI devices have emerged,
including the Lotus valve (Boston Scientific Inc, USA),31 with
promising results for various procedural outcomes.
4. Anesthetic considerations
Our center (1st University Department of Cardiology, Hip-
pokration Hospital, Athens) was one of the very first TAVI
centers in Greece and has performed more than 400 im-
plantations since the beginning of 2009. At the start of the
TAVI program, all transfemoral procedures were performed
under GA. Subsequently, with gained experience and use of
newer devices, we have opted to perform more than 90% of
the implantations with only LA and mild sedation. When
surgical access is necessary, for example, with use of the
trans-subclavian route, GA is obviously mandatory.
All patients receive antibiotic prophylaxis (piperacillin-
tazobactam and/or vancomycin, dosage according to renal
function) 1 h before the procedure, and are on dual anti-
platelet treatment (100 mg acetylsalicylic acid and 75 mg
clopidogrel, daily).
4.1. General anesthesia (GA)
Invasive anesthesia monitoring consists of a three-lumen cen-
tral line (standard jugular veinaccess) for theadministrationofgy considerations for the trans-catheter aortic valve implantation
i.org/10.1016/j.hjc.2016.10.001
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line for invasive blood pressure monitoring and/or blood gas
control.A5e6Frenchsheath isalso inserted in the jugularvein,
which can be used by the cardiologist to fluoroscopically posi-
tiona temporarypacemakerwire in the rightventricleapex.All
lines are inserted once the patient lies on the cath lab table.
Basic non-invasive monitoring consists of pulse oximetry, cap-
nography, continuous multiple channel ECG and hourly urine
output through a bladder catheter.
Since the anesthetist controls the cardiac pacing, we
will briefly provide details. During balloon inflation in cases
of aortic valvuloplasty, a brief run of rapid ventricular
pacing at 170e200 beats per minute is necessary to drop
the blood pressure below 50 mmHg systolic and facilitate
immobility of the expanding balloon. The same maneuver is
performed during expansion of balloon-expandable pros-
theses, i.e., those of the Edwards family. After each run,
the pacemaker is reverted to 50 beats per minute back-up
pacing; in rare occasions (2e5%) where the valvuloplasty
results in a severe aortic regurgitation, fast pacing of
approximately 100e120 bpm is used to stabilize the patient
during the few minutes that are necessary to deploy the
prosthesis.
The choice of anesthetic agents varies. Induction is
usually performed with the use of midazolam, ketamine,
fentanyl and etomidate, or propofol, which are titrated
accordingly; all but the last are considered cardiovascular
stable drugs that do not cause a clinically significant drop in
the blood pressure and/or pulse rate. However, some pa-
tients may require inotropic and/or vasopressor support
before the induction of anesthesia; therefore, infusion
drips of noradrenaline (and less often adrenaline or phen-
ylephrine) are prepared and ready to be administered.
Rocuronium is used to facilitate endotracheal intubation.
Generally, however, the manner of drug administration
(dosage, etc.), rather than which specific drug is used, is
more important for achieving hemodynamic stability during
anesthesia induction and endotracheal intubation. Hemo-
dynamic collapse in an elderly, frail patient with significant
aortic valve stenosis provides very little time and few op-
tions before full-blown cardiac arrest.
The maintenance of anesthesia is achieved with a
target-controlled infusion of propofol. An added benefit of
GA and endotracheal intubation is the option to perform
trans-esophageal echocardiography (TEE) during the TAVI
procedure, either routinely or on an as-needed basis. The
latter is the protocol in our center.
4.2. Local anesthesia (LA) and sedation
All invasive lines are inserted in the same way as that
described for the GA approach. Oxygen is administered
with a partial rebreathing face-mask, and end-tidal carbon
dioxide is measured (capnography). LA is performed by the
interventional cardiologist per standard techniques (2%
lidocaine injection bilaterally in the two groin areas).
Sedation is performed by the anesthesiologist and consists
of target-controlled administration of midazolam, propo-
fol, fentanyl or remifentanil alone or in various dosage
combinations. The dosage and rate of administration are
individualized and titrated to the desired effect, according
to clinically relevant factors, including concomitantPlease cite this article in press as: Melidi E, et al., Cardio-anesthesiolo
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patient debilitation. In all cases, access to the patient is
such that the airway can be secured easily, if needed.
5. Choice of anesthesia
The most important anesthetic consideration in TAVI is the
type of anesthesia that will be given to the patient. Trends
vary within hospitals and countries, and numerous factors
need to be considered before reaching a decision, including
patient-related and operational factors as well as logis-
tics.32 In the early years of TAVI, GA was the default
option33e36; as previously mentioned, this was also the
standard in our hospital.
GA enables the use of either two- or three-dimensional
TEE, which can theoretically assist in optimal valve
deployment and prompt recognition of complications, such
as tamponade, interference with the mitral valve or para-
valvular leakage. Although the use of TEE with GA and
sedation has been described,37 most centers (including
ours) with adequate experience do not perform TEE;
instead, they rely on transthoracic echocardiogram (TTE),
angiography and hemodynamic measurements. Multi-slice
computed tomography is routinely utilized for valve size
selection, whereas the probe from the TEE interferes with
fluoroscopic imaging during valve deployment; however, a
pigtail catheter in the non-coronary cusp is sufficient for
guiding the procedure.38
Operators use GA in cases where the trans-femoral route
is not possible and surgery is involved, including the sub-
clavian,14 trans-aortic15 and trans-apical16 routes. Although
subclavian cases have been reported with LA, most centers
still prefer GA for these TAVI cases.39e41
Another theoretical argument in favor of GA is the total
immobility of the patient, which could decrease compli-
cations. However, available evidence does not support this
concern, indicating that the type of anesthesia is irrelevant
to the occurrence of vascular complications.34,35,41e44
The type of the anesthetic management has increasingly
switched from GA to LA, especially in European centers.45
Sedation shortens procedural time, time to ambulation
and hospital stay duration.34 In addition, the use of vaso-
pressors in sedation is not as frequent as in GA procedures,
which can be attributed to the vasodilating effects of the
anesthetic agents.46,47 Furthermore, emergency intubation
and switching to GA can be achieved in the cath lab to
surgically handle cardiac or vascular complications should
they arise during TAVI.48,49
LA has the unique benefit of real-time evaluation of the
patient’s mental status and cognitive function. Favorable
outcomes with a shorter implant procedure time, reduced
stay in high dependency areas, and shorter time to hospital
discharge have been reported in a series of patients who
underwent TAVI under sedation with remifentanil.34
6. Post-procedural care
After the procedure, patients are transferred to the coro-
nary care unit (CCU) for observation; GA patients are
extubated in the cath lab and are then transferred to the
CCU. For transfemoral TAVI, simple analgesics or low dosegy considerations for the trans-catheter aortic valve implantation
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gesia is only required when a surgical incision has been
made. After the procedure, improvements in systolic and
diastolic functions are often observed due to afterload
lowering, thus allowing for reduction or even discontinua-
tion of inotropic drugs.50 Sometimes high levels of crystal-
loids (i.e., normal saline, 0.9%) are needed during the
initial post-procedural hours to support a chronically hy-
pertrophied small left ventricle.
In uncomplicated cases of the “modern” TAVI era that
use 14 French devices, the patient is mobilized after 24 h.
In cases where there is no need for ECG monitoring, for
example, if a permanent pacemaker was in place prior to
the TAVI procedure, the patient is discharged after 2 to 3
days. In experienced centers, early discharge after the
procedure is becoming more prevalent; same-day discharge
has been described in a patient who underwent trans-
femoral TAVI with LA.51 However, it must be emphasized
that same-day discharge is not yet safe or common.7. Complications
From the available data, there is no difference between GA
and LA in terms of mortality.45,52 European data have shown
that patients with high EuroSCORE levels undergoing TAVI
with GA have a higher mortality, highlighting the need for
better evaluation and the possible use of LA in these
patients.38
It is also an important to monitor renal function after the
procedure. Impaired renal function before TAVI is considered
a prognostic factor for mortality after the procedure.53 Many
factors can influence renal function during the procedure,
including the amount and type of contrast, the incidence of
debris embolization during valvuloplasty and/or valve
deployment and the occurrence of hypotensive episodes
triggered by anesthetic agents.38 Recent reports have shown
higher rates ofacute kidney injury in theGApopulation,which
are attributed to episodes of hypotension.52,54,55 However,
there remains a lack of robust data regarding any possible
effect the type of anesthesia might have on kidney function.
Pacemaker implantation after TAVI is another important
consideration, and rates vary depending on the valve type
that is being used, the depth of implantation and the ex-
istence of previous conduction defects.56e59 While multiple
TAVI registries have not found any difference between the
anesthesia type and pacemaker implantation rates,32,45 one
single registry did.52 Nonetheless, it is inconclusive whether
the type of anesthesia impacts the incidence of pacemaker
implantation.
One of the most feared complications during TAVI is the
possibility of a stroke. It has been reported that patients are
more worried about stroke than death.50 Both PARTNER trial
cohorts, comparing the Edwards TAVI with either SAVR or
medical therapy, showed an increase in the rates of stroke in
the TAVI population during the first year.25,27 Longer follow-
up data from this trial have shown that at 5 years, the rates of
stroke in both the TAVI and SAVR populations are equal.60
Data from available trials and studies have not shown any
association between the types of anesthesia and the rates of
strokeafter TAVI.45,52,61 In theory, because LAhas thebenefit
of real-time evaluation of the patient’s mental status andPlease cite this article in press as: Melidi E, et al., Cardio-anesthesiolo
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treated, more easily and quickly.
From a financial point of view, frequent reports suggest
that LA with sedation in TAVI is more cost-effective
compared to GA since it requires less hospital staff and a
shorter length of hospital stay; however, reliable data are
still needed.54,62,63
8. Clinical implications
The rates of TAVI procedures have increased in the past
decade, enabling more patients with symptomatic aortic
stenosis to be successfully treated. Interestingly, this in-
crease in the use of TAVI has not decreased the number of
SAVR procedures performed, indicating the importance of
TAVI in meeting a previously unmet need for these pa-
tients.64 However, it is still unknown whether this might
change in the future, as the number of TAVI procedures
could eventually surpass SAVR procedures. The crucial
determining factor for this shift will be newer indications
for TAVI that we presume are forthcoming, including use in
intermediate- and lower-risk populations and in patients
with bicuspid aortic valves or failing bioprosthetic valves.65
The type of anesthesia during TAVI is an ongoing matter
for debate. There is a wealth of data that can be found in
various registries and studies, but no randomized controlled
trials. There has been a steady change in practice with the
ongoing trend to use local anesthesia with mild sedation
more; this approach has many potential benefits, including
shorter operative time, direct communication with the
patient, potentially lower complication rates and reduced
need for intra-procedural vasopressor support. However,
there remains a need for GA, especially when unconven-
tional access routes are indicated. The importance of the
presence of a dedicated and experienced cardiac-
anesthetist at the patient’s head at all times during the
TAVI procedure cannot be overemphasized. All described
anesthesia steps should be meticulously followed to assist
the interventional cardiologists in the procedure and to
minimize complications and immediately help resolve them
should they occur.
9. Conclusion
Transcatheter aortic valve implantation is a promising
treatment strategy for high-risk surgical patients, and trials
investigating its effectiveness in intermediate- and lower-
risk patients are underway. Data are inconsistent regarding
the superiority of using local anesthesia with conscious
sedation alone versus general anesthesia as the anesthesia
management of choice for elderly frail patients. Ultimately
and at present, the choice of anesthesia is based on the
personal experience and preference of the Heart Team
involved in the TAVI procedure, which will dictate the best
possible management plan for each patient.References
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